title: The role of front-line anthracycline-containing chemotherapy regimens in peripheral T-cell lymphomas.
abstract: Peripheral T-cell lymphomas (PTCLs) are a heterogenous group of aggressive non-Hodgkin's lymphomas that are incurable in the majority of patients with current therapies. Outcomes associated with anthracycline-based therapies are suboptimal, but remain the standard of care for most patients, even though the benefits of this approach remain uncertain. This study retrospectively examined outcomes in a cohort of North American PTCL patients treated with both anthracycline- and nonanthracycline-containing regimens. The incorporation of anthracycline-containing regimens was associated with improved progression-free survival (PFS) and overall survival (OS). Patients treated with nonanthracycline-containing regimens were more likely to have high-risk features and were less likely to undergo high-dose therapy and stem cell transplantation. However, anthracycline use remained an independent predictor of improved PFS and OS when adjusting for these confounding variables. Anthracycline-based regimens and consolidation with high-dose therapy and autologous stem cell transplantation in appropriately selected patients remains a viable option for patients unable to participate in a clinical trial. Long-term disease-free survival is not optimal, highlighting the need for an improved understanding of disease pathogenesis, and the development of novel therapeutic strategies.
authors.affiliation: Department of Internal Medicine, Division of Hematology and Oncology, University of Michigan, Ann Arbor, MI, USA.
authors.forename: R
authors.initials: R
authors.lastname: Briski
authors.affiliation: Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
authors.forename: A L
authors.initials: AL
authors.lastname: Feldman
authors.affiliation: Department of Pathology, University of Michigan, Ann Arbor, MI, USA.
authors.forename: N G
authors.initials: NG
authors.lastname: Bailey
authors.affiliation: Department of Pathology, University of Michigan, Ann Arbor, MI, USA.
authors.forename: M S
authors.initials: MS
authors.lastname: Lim
authors.affiliation: Department of Internal Medicine, Division of Hematology, Mayo Clinic, Rochester, MN, USA.
authors.forename: K
authors.initials: K
authors.lastname: Ristow
authors.affiliation: Department of Internal Medicine, Division of Hematology, Mayo Clinic, Rochester, MN, USA.
authors.forename: T M
authors.initials: TM
authors.lastname: Habermann
authors.affiliation: Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
authors.forename: W R
authors.initials: WR
authors.lastname: Macon
authors.affiliation: Department of Internal Medicine, Division of Hematology, Mayo Clinic, Rochester, MN, USA.
authors.forename: D J
authors.initials: DJ
authors.lastname: Inwards
authors.affiliation: Department of Internal Medicine, Division of Hematology, Mayo Clinic, Rochester, MN, USA.
authors.forename: J P
authors.initials: JP
authors.lastname: Colgan
authors.affiliation: Department of Internal Medicine, Division of Hematology, Mayo Clinic, Rochester, MN, USA.
authors.forename: G S
authors.initials: GS
authors.lastname: Nowakowski
authors.affiliation: Department of Internal Medicine, Division of Hematology and Oncology, University of Michigan, Ann Arbor, MI, USA.
authors.forename: M S
authors.initials: MS
authors.lastname: Kaminski
authors.affiliation: Department of Internal Medicine, Division of Hematology, Mayo Clinic, Rochester, MN, USA.
authors.forename: T E
authors.initials: TE
authors.lastname: Witzig
authors.affiliation: Department of Internal Medicine, Division of Hematology, Mayo Clinic, Rochester, MN, USA.
authors.forename: S M
authors.initials: SM
authors.lastname: Ansell
authors.affiliation: Department of Internal Medicine, Division of Hematology and Oncology, University of Michigan, Ann Arbor, MI, USA.
authors.forename: R A
authors.initials: RA
authors.lastname: Wilcox
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018943:Anthracyclines / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D015331:Cohort Studies; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D016411:Lymphoma, T-Cell, Peripheral / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D055815:Young Adult
chemical_list: D018943:Anthracyclines